PT  - JOURNAL ARTICLE
AU  - Jiahao Shi
AU  - Tianyu Zhu
AU  - Min Zhou
AU  - Xiaowen Zhou
AU  - Xin Song
AU  - Yefei Wang
AU  - Renbing Jia
AU  - Ziyao Yu
AU  - Yixiong Zhou
AU  - Xianqun Fan
TI  - Predicting the risk of distant and local recurrence for patients with ocular adnexal extranodal marginal zone lymphoma: a matched case–control study
AID  - 10.1136/bjo-2022-321656
DP  - 2022 Aug 01
TA  - British Journal of Ophthalmology
PG  - bjophthalmol-2022-321656
4099  - http://bjo.bmj.com/content/early/2022/08/01/bjo-2022-321656.short
4100  - http://bjo.bmj.com/content/early/2022/08/01/bjo-2022-321656.full
AB  - Background/aims Extranodal marginal zone lymphoma of ocular adnexa (OA-EMZL) is the most frequent type of ocular adnexal lymphomas, with a high rate of disease recurrence. Precise patient stratification based on disease recurrence is understudied. This study aims to identify risk factors of distant recurrence (DR) and local recurrence (LR) to construct a prognostic model optimising rapid decision of therapeutic strategies.Methods A total of 104 patients diagnosed with OA-EMZL between January 2011 and February 2020 were enrolled. Propensity score matching was performed for DR and LR groups. A nomogram was generated using a multivariate Cox proportional hazards model.Results After matching, different independent risk factors of DR and LR were identified. Monocyte percentage (p=0.015) and M category >0 (p=0.043) were significant independent risk factors of DR. Epiphora (p<0.001) was the significant independent risk factor of LR. Three factors (monocyte percentage, M category >0, age >60) were integrated into the nomogram to predict the risk of DR. It had a relatively better discriminative ability for distant recurrence-free survival (C-index: 3-year, 0.784; 6-year, 0.801) than IPI score (C-index: 3-year, 0.663; 6-year, 0.673) in the cohort of all patients.Conclusion Our analyses suggested DR and LR as two distinct prognostic events, and additionally identified novel risk factors of them. The nomogram may serve as a practical tool for the prognostic estimation and rapid decision of therapeutic strategies for patients with OA-EMZL.Data are available upon reasonable request. Data are available upon reasonable request. The data used to support the findings of this study are available from the corresponding author upon request.